Softox Solutions As · OSL:SOFTX
Softox Solutions As — DNB Healthcare Conference 2022
20 slides from Softox Solutions As's conference presentation, Dec 15, 2022
Slide 1: SoftOx Solutions AS
SoftOx Solutions AS Unique antimicrobial platform technology with application to Wound Care & Infectious Disease treatment and prevention DNB HEALTHCARE CONFERENCE 2022 15 December 2022
Slide 2: Forward-looking statement
Forward-looking statement Certain statements contained in this presentation constitute forward-looking statements. Forward-looking statements are statements that are not historical facts, and they can be identified by the use of forward-looking terminology, including the words "anticipate", "believe
Slide 3: Today's presenters from SoftOx management
Today’s presenters from SoftOx management Geir Hermod Almås Dr Christopher Burton Chief Executive Officer Chief Medical Officer MSc (Norwegian Business School - BI) MA (Cambridge University) Chartered Accountant (Norwegian School of MD (Imperial College London) Economics, NHH) PhD (University of Cop
Slide 4: SoftOx – Key takeaways
SoftOx – Key takeaways Clinical studies of wound technology – showing consistent reduction in wound bacterial burden and dose-dependent reduction in wound size after just 5 days’ treatment Clinical study of respiratory technology - showing favourable tolerability and safety with preclinical proof of
Slide 5: Network-based product development
Network-based product development PARTNERS Preclinical Proof Clinical Proof Concept development PARTNERING of Concept of Concept DE-RISKING FROM CO-FUNDERS AND PARTNERS Investment phase Cash flow Commercial, Industry & Financial Partners Clinical Partners Academic Research Partners Key Opinion Leade
Slide 6: Product pipeline – Good progress in clinical development programs
Product pipeline – Good progress in clinical development programs Business Regulatory segments Projects Pre-clinical Phase I Phase II approval Collaborations Hand and surface KemI (Sweden) disinfectants granted 10-2022 Disinfection (SafeDes & EffectDes) PARTNERING Wound irrigation solution Wound Car
Slide 7: SoftOx technology – a stable and long-lasting product with unique combination effects
SoftOx technology – a stable and long-lasting product with unique combination effects 1. SOFTOX TECHNOLOGY 2. Strong pan-spectrum antimicrobial (virucidal/bactericidal) effects HYPOCHLOROUS ORGANIC ACID ACID 3. Not shown to induce antimicrobial resistance Documented broad Antimicrobial antimicrobial
Slide 8: HOCl has direct and indirect antimicrobial MoA
HOCl has direct and indirect antimicrobial MoA: Independent of biological processes and unreliant on a metabolic target or receptor Disrupts microbial replication & host cell entry Disrupts microbial integrity & repair Disrupts nucleic acid synthesis & metabolism Increases microbial immunogenicity S
Slide 9: Business segments
Business segments Infectious disease Wound care Disinfection Treatment of viral infections Treatment for acute and Infection prevention and biological chronic wounds solutions for hands and countermeasure development surfaces SoftOx in brief SoftOx technology Business segments
Slide 10: Business segment: Infectious disease
01 Business segment: Infectious disease
Slide 11: Respiratory infectious diseases are the third leading cause of death worldwide
Respiratory infectious diseases are the third leading cause of death worldwide1 and pose significant socioeconomic costs Limitation of vaccines Need for a novel, self-administered, product with broad-spectrum, antiviral and antibacterial effects Morbidity & mortality Need for early antimicrobial int
Slide 12: Pre-clinical proof of concept: infection prevention in a mouse model
Pre-clinical proof of concept: Demonstration of infection prevention in a mouse model Co-housing with infected mice & exposure prophylaxis Saline Treatment Group with Saline or SoftOx DAY 5 SoftOx Treatment Group Index (infected) mouse removed from cohousing on day 3 Uninfected mouse Infected mouse
Slide 13: Nebulised formulation safe and well tolerated
Nebulised formulation safe and well tolerated Abstract presented to ERS 2022 • No SAEs • Mild, self-limiting AEs related/unrelated to drug administration • Acceptable local tolerability • No effect on spirometry, vital signs, ECG or safety laboratory values At all dose levels Regardless of dosing fr
Slide 14: Market potential of aerosolised SoftOx formulations
Market potential of aerosolised SoftOx formulations Example roll out across indications and evolution of price vs. volume Acute Exacerbation of COPD prevention Volume: Influenza like-illness treatment +/- Price: prevention Volume: Price erosion compensated by larger Hospital acquired, Price: increas
Slide 15: Business segment: Wound care
02 Business segment: Wound care
Slide 16: Significant unmet need for effective treatment in wound care
Significant unmet need for effective treatment in wound care Wound UNMET NEED: 6.5 million Patient population drivers: • Obesity $25 billion chronic wound patients • Diabetes Annual treatment costs of chronic in the US • Population over 65 years of age wounds in US POTENTIAL MARKET: Lack of innovati
Slide 17: An effective wound product must be broad spectrum
An effective wound product must be broad spectrum because of Wound many types of bacteria in the wound VLU Bacteriology 1 Percentage of wounds colonised (%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Representative CLSM images of S. aureus (A and B), P. aeruginosa (C and D). Arrows point to the wou
Slide 18: Safe and well tolerated in patients with chronic leg wounds
Safe and well tolerated in patients with chronic leg wounds: Wound Observed reductions in bacterial burden and wound size with dose response > 99% reduction up to 36% improvement in bacterial bioburden in wound healing after 5 days 1.000.000 Absolute bacterial bioburden to 10.000 Relative Change fro
Slide 19: First indication gives large market opportunities
First indication gives large market opportunities Wound UNMET NEED: 6.5 million Patient population drivers: • Obesity $25 billion chronic wound patients • Diabetes Annual treatment costs of chronic in the US1 • Population over 65 years of age wounds in US1 POTENTIAL MARKET: Compared to usual care, a
Slide 20: Unique platform technology, 70+ patents
Unique platform Significant unmet Technology reinforcing technology medical needs in nature’s own ability to with combination effects wound care and infection eradicate unwanted & supported by clinical disease microbes evidence For further information, please contact Contact Information: ir@soft-ox.